SCHEMBL25516484

SCHEMBL25516484

CC(C)N(CC#N)S(=O)(=O)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.47
HTT P42858 2/20 0.45
TSHR P16473 2/20 0.45
MAPT P10636 1/20 0.45
MAPK1 P28482 1/20 0.45
ESR2 Q92731 1/20 0.43
MMP2 P08253 1/20 0.43
MMP9 P14780 1/20 0.43
MMP8 P22894 1/20 0.43
MMP13 P45452 1/20 0.43
MAOB P27338 1/20 0.42
APOBEC3G Q9HC16 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
KDM4E B2RXH2 2/20 0.41
HIF1A Q16665 1/20 0.40
EPAS1 Q99814 1/20 0.40
NR1I2 O75469 1/20 0.40
CCR5 P51681 1/20 0.40
KEAP1 Q14145 2/20 0.39
NFE2L2 Q16236 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25520640 0.87 GLA (0.43) GLAHTTTSHRMAPTMAPK1
SCHEMBL25518489 0.79 GLA (0.50) GLAESR2MMP9MMP13MAOB
SCHEMBL25519385 0.78 TDP1 (0.46) GLAHTTMAPTMMP2MMP9
SCHEMBL25523725 0.78 TDP1 (0.46) GLAHTTMAPTESR2MMP2
SCHEMBL25523717 0.77 TDP1 (0.44) GLAHTTMAPTMMP2MMP9
SCHEMBL3653180 0.77 ESR2 (0.50) HTTTSHRMAPTMAPK1ESR2
SCHEMBL3483564 0.77 HTT (0.48) HTTTSHRMAPTMAPK1ESR2
SCHEMBL24712459 0.76 HSD11B1 (0.42) GLAMAPTMAOBKDM4ECCR5
SCHEMBL25518493 0.76 GLA (0.60) GLAHTTTSHRMAPTTDP1
SCHEMBL5192024 0.75 HTT (0.67) HTTTSHRMAPTMAPK1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159569-A1 DUAL HDAC6/PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF UNIVERSITY OF MARYLAND, BALTIMORE (US) 2023-05-25 US disclosed
US-20230159569-A1 DUAL HDAC6/PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF UNIVERSITY OF MARYLAND, BALTIMORE (US) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159569-A1 DUAL HDAC6/PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF HDAC6, PSMG3, PSMB2 GLA 1167/4885HTT 339/4885TSHR 4223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.